is tirzepatide safe for kidneys SURPASS-4: slows kidney disease in adults with type 2 diabetes, CV risk SURPASS-4: Tirzepatide slows kidney disease

Description

Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker.The impact of triple therapy on CV outcomes remains difficult to discern

With drugs like Ozempic and Wegovy growing in popularity among diabetic patients, CRNAs must be aware of all potential GLP-1 and anesthesia conflicts.

Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular benefits in type 2 diabetes, but none of the cardiovascular trials studied atrial fibrillation/atrial flutter (AF) as a primary endpoint

The semaglutide shortage could be lifted any day, according to data analysis of past shortages on archived FDA webpages and interviews with industry experts.

While both target weight loss through different mechanisms, dual therapy carries cardiovascular and metabolic risks that demand provider oversight and individual assessment before proceeding